Keyphrases
7q Deletion
7%
Acute Lymphoblastic Leukemia
6%
Acute Myeloid Leukemia
100%
Acute Promyelocytic Leukemia
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Array Profiling
11%
Asparagine Synthetase
11%
Associated Genes
17%
Cancer Progression
10%
CD8+ T Cells
8%
Chemotherapy
12%
Chromosome 7
6%
Complete Remission
11%
Cutaneous Squamous Cell Carcinoma (cSCC)
11%
Del(7q)
7%
DNA Damage
6%
Hematopoietic Stem Cells
9%
Immune Checkpoint Blockade
9%
In Cancer
7%
Intensive Chemotherapy
8%
Leukemia
20%
Leukemia Patients
17%
MDM2-p53 Interaction
6%
Microenvironment
6%
MicroRNA
17%
Minimal Residual Disease
6%
Murine Double Minute 2 (MDM2)
7%
Myelodysplastic Syndrome
6%
Newly Diagnosed
20%
Non-small Cell Lung Cancer (NSCLC)
12%
Np63
18%
Overall Survival
12%
P53 Activity
6%
Phase II Trial
6%
Prognostic Role
6%
Proteome Array
11%
Relapsed or Refractory
7%
Reversed Phase
11%
Sickle Cell Disease
11%
Single Center
11%
Squamous Cell Carcinoma (SqCC)
9%
Stem Cells
7%
T Cells
6%
TAp63
17%
Therapeutic Strategies
10%
TP53 Alterations
6%
TP53 mutation
10%
Tumor
7%
Tumor Protein p53 (TP53)
9%
Venetoclax
27%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
7%
Acute Myeloid Leukemia
88%
Allogeneic Stem Cell Transplantation
6%
Arm
8%
Aspartate Ammonia Ligase
11%
Cancer Growth
6%
Cell Cycle
5%
Cell-Free DNA
5%
Cellular Stress Response
6%
Combination Therapy
6%
COVID-19
5%
Diseases
20%
Enhancer Region
5%
Immunity
12%
Immunotherapy
6%
Karyotype
5%
Leukemia
16%
Lung Cancer
6%
Malignant Neoplasm
27%
microRNA
17%
Milademetan
5%
Mucositis
5%
Myeloid Sarcoma
5%
Natural Killer Cell
6%
Neonatal Infant
9%
Neonate
11%
Neoplasm
19%
Newborn Screening
6%
Offspring
7%
Oncologist
6%
Overall Survival
21%
Pediatrics
7%
Pediatrics Patient
7%
Phlebotomy
5%
Polycystic Ovarian Syndrome
5%
Precancerous Condition
6%
Prevalence
11%
Protein P53
12%
Proteomics
16%
Recurrence Free Survival
6%
Sickle-Cell Disease
11%
Skin Carcinoma
11%
Squamous Cell Carcinoma
6%
Stem Cell
6%
Stem Cell Therapy
12%
T Cell
7%
Tertiary Care
5%
Thalassemia Major
5%
Transcriptomics
6%
Venetoclax
23%